The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players ... grew ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The Big Pharma companies made a last-ditch effort asking a U.S. appeals court to reconsider their lawsuits against the ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Lawyers for AstraZeneca , Bristol Myers Squibb and Johnson & Johnson's Janssen on Wednesday urged a federal appeals court in ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...